Characteristic | All (n = 35) | Warfarin user (n = 12) | Non-warfarin user (n = 23) |
---|---|---|---|
Age (years) | 61 (51–77) | 65.5 (52.5–79) | 59 (51–74) |
Male | 25 (71%) | 8 (67%) | 17 (74%) |
PT-INR at trough | 1.39 (1.12–2.38) | 2.62 (1.63–3.29) | 1.19 (1.06–1.42) |
Time interval between trough and peak (min) | 105 (95–120) | 95 (95–110) | 112.5 (90–120) |
Daptomycin dose (mg/kg/dose) | 6.0 (5.9–6.1) | 6.0 (5.9–6.4) | 6.0 (5.8–6.0) |
Number of daptomycin administered before peak | 4 (3–5) | 4.5 (4–5.5) | 4 (3–5) |
Creatinine clearance (mL/min) | 84.8 ± 54.1 | 74.2 ± 40.4 | 89.9 ± 59.7 |
Source of infection | |||
Skin/joint infection | 19 (54%) | 7 (58%) | 12 (52%) |
Bacteraemia | 12 (34%) | 5 (42%) | 7 (30%) |
Other infections | 4 (11%) | 0 (0%) | 4 (17%) |
Comorbidity | |||
Autoimmune disease | 5 (14%) | 2 (17%) | 3 (13%) |
Cancer | 6 (17%) | 2 (17%) | 4 (17%) |
Cardiovascular disease | 13 (37%) | 8 (67%) | 5 (22%) |
Others | 11 (31%) | 0 (0%) | 11 (48%) |
Concomitant antibiotic use | 17 (49%) | 7 (58%) | 10 (43%) |